Twelve percent of US adults have now tried a GLP-1 medication, six percent are actively on one, and analysts project the active user base in North America will reach roughly thirty million by 2030. Canadian adoption sits about twenty percent higher per capita than the United States, which means Canadian operators are seeing the downstream effects earlier and harder than their American peers. Sixty-three percent of users report spending less at restaurants. Fifty percent report fewer restaurant visits overall. That is not a marketing dip or a recession blip. It is a structural shift in how a growing slice of the population buys food away from home.
The signal reached the main stage of the National Restaurant Association Show in 2026 with a panel titled The GLP-1 Effect, and Gordon Food Service Canada named Nutrient-Dense Shift the number one trend operators should plan for this year. These are not fringe indicators.







